MADIA (Magnetic Diagnostic Assay for Neurodegenerative Diseases)
MADIA will develop a versatile and cost-effective in-vitro tool for early diagnosis of Alzheimer and Parkinson diseases. Alzheimer and Parkinson diseases, the two most common neurodegenerative disorder worldwide, are debilitating and largely untreatable conditions that are strongly linked with age. MADIA aims at fabricating devices based on arrays of magnetic sensors integrated into a microfluidics device and capable of recognising biomarkers, obtained from cerebrospinal fluid or blood samples, conjugated with ultra-small magnetic nanoparticles. This will allow the early diagnosis of Alzheimer and Parkinson diseases and improve the efficacy of current therapies which have been shown to slow the progression, particularly of Parkinson disease, as currently there is no cure for either disease. MADIA has the ambition to move the AD and PD diagnostic ability significantly beyond the state of the art by increasing the sensitivity against selected biomarkers by Three orders of magnitude and by advancing for the first time an in vitro diagnostic technology able to sense the protein unfolding pathologies leading to harmful aggregations like oligomers, fibrils, plaques. Such ambitious results are expected thanks to the integration of 3 innovative technologies, namely Functionalised magnetic nanoparticles (MNPs), Magnetic sensors and Microfluidics.
Degree of documentation